Carol S O'Brien from Orinda, CA, age 86

Name / Title

Company / Classification

Phones & Addresses

Carol O'Brien
Executive Director

Arapahoe Douglas Area
Other Technical & Trade Schools · Colleges and Universities · Schools-Industrial Technical &

2400 W Alamo Ave, Littleton, CO 80120
(303)7975080, (303)7975083

Carol O'Brien
CTO

Fidelity National Title
Title Insurance Carrier · Real Estate Agent/Manager · Title Insurance Carrier Title Abstract Office · Real Estate Agents · Direct Title Insurance Carriers

451 E Vanderbilt Way, San Bernardino, CA 92408
3633 Inland Empire Blvd, Ontario, CA 91764
301 E Vanderbilt Way, San Bernardino, CA 92408
(909)9491989, (909)8900601, (760)8430776, (909)4669002

Lawyers & Attorneys

Carol O'Brien - Lawyer

view source

Specialties:

Communications Law
Intellectual Property
Advertising and Marketing

ISLN:

913165452

Admitted:

1998

Law School:

University of Ottawa, LL.B., 1996

Carol O'Brien - Lawyer

view source

Specialties:

Criminal
Criminal Defense

ISLN:

911348093

Admitted:

1983

University:

Northwestern University, B.A., 1980

Law School:

University of Toledo, J.D., 1983

Resumes

Carol O'brien Modesto, CA

view source

Work:

Memorial Medical Center

Feb 2009 to Present
Patient Services Little Sisters of the Poor Skilled Living Facility
Saint Paul, MN
Jul 2006 to Oct 2008
Medical Records Secretary/Appointment Scheduler Cal-tron Engineering
Walnut Creek, CA
Nov 1991 to Sep 2004
Shipping/Receiving Manager

Education:

California State University, Stanislaus
Turlock, CA
Jan 2005 to Jan 2005
Certificate of Completion in Medical Office Assistant,

Skills:

Proficient in Microsoft Office and Word programs

Us Patents

Modulating Insulin Receptor Signaling Through Targeting Facl
view source
US Patent:

20030138832, Jul 24, 2003
Filed:

Dec 18, 2002
Appl. No.:

10/322855
Inventors:

Lisa Kadyk - San Francisco CA, US
Carol O'Brien - Castro Valley CA, US
International Classification:

C12Q001/68
G01N033/53
US Classification:

435/006000, 435/007100
Abstract:

Human FACL genes are identified as modulators of INR signaling and thus are therapeutic targets for disorders associated with defective INR signaling. Methods for identifying modulators of FACL, comprising screening for agents that modulate the activity of FACL are provided.

Genetic Variations Associated With Drug Resistance
view source
US Patent:

20110177099, Jul 21, 2011
Filed:

Mar 12, 2009
Appl. No.:

12/922420
Inventors:

Mark Lackner - South San Francisco CA, US
Lukas C. Amler - Foster City CA, US
Guy Cavet - Burlingame CA, US
Carol O'Brien - Pacifica CA, US
Ajay Pandita - Redwood City CA, US
International Classification:

A61K 39/395
C12Q 1/68
C40B 30/04
G01N 33/574
A61K 31/713
A61P 35/00
US Classification:

4241741, 435 611, 506 9, 435 71, 514 44 A, 4241781
Abstract:

Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.

Treatment Of Cancer Having Gnaq Or Gna11 Genetic Mutations With Protein Kinase C Inhibitors
view source
US Patent:

20220305008, Sep 29, 2022
Filed:

Jan 7, 2020
Appl. No.:

17/420833
Inventors:

- South San Francisco CA, US
Mark Lackner - San Mateo CA, US
Zineb Mounir - Pacifica CA, US
Carol O'Brien - Brisbane CA, US
International Classification:

A61K 31/497
A61K 31/506
C12Q 1/6886
A61P 35/00
Abstract:

The present disclosure relates in part to methods for treating non-uveal melanoma cancers having GNAQ or GNA11 genetic mutations that include administering a PKC small molecule inhibitor.

Genetic Variations Associated With Drug Resistance
view source
US Patent:

20180298387, Oct 18, 2018
Filed:

Dec 11, 2017
Appl. No.:

15/838042
Inventors:

- South San Francisco CA, US
Lukas C. Amler - Foster City CA, US
Guy Cavet - Burlingame CA, US
Carol O'Brien - Pacifica CA, US
Ajay Pandita - Redwood City CA, US
International Classification:

C12N 15/113
C12Q 1/6886
A61K 47/68
Abstract:

Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.